Lutetium Lu 177 Vipivotide Tetraxetan trials for Stage IVB Prostate Cancer AJCC v8
All Lutetium Lu 177 Vipivotide Tetraxetan trials · All Stage IVB Prostate Cancer AJCC v8 trials
7
Recruiting trials
Phase breakdown
Phase 1 1Phase 2 5Phase 3 1
Recruiting trials studying Lutetium Lu 177 Vipivotide Tetraxetan for Stage IVB Prostate Cancer AJCC v8
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Common questions
How many trials study Lutetium Lu 177 Vipivotide Tetraxetan for Stage IVB Prostate Cancer AJCC v8?
7 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.